Marlowe plc (MRLWF)

Marinus Pharmaceuticals Cash Flow Statement

Financials in millions GBP. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Net Income	141.1	-10.2	-3.8	0.7	-1.7
Depreciation & Amortization	20.7	33.7	33.8	23.8	14.3
Other Amortization	2	4.9	5.9	4	1.5
Loss (Gain) From Sale of Assets	-0.2	-0.2	-	-	-
Asset Writedown & Restructuring Costs	-	-	-	10.5	5.7
Stock-Based Compensation	2	-0.8	1.7	1.9	4.2
Other Operating Activities	0.3	1.9	1.2	-11.9	-6.8
Change in Accounts Receivable	6.6	-1.2	-12	-15	0.3
Change in Inventory	-0.5	-	-1.7	-2.1	0.3
Change in Accounts Payable	0.4	-1.1	5.3	-3.3	2.6
Operating Cash Flow	33	-19.7	33.6	8.6	20.4
Operating Cash Flow Growth	-	-	290.70%	-57.84%	500.00%
Capital Expenditures	-9.2	-14.4	-16.4	-9.1	-4.5
Sale of Property, Plant & Equipment	458.6	1.4	1.4	1.1	0.6
Cash Acquisitions	-0.7	-31.7	-59	-316	-68
Other Investing Activities	-	4.3	-	-	-
Investing Cash Flow	448.7	-40.4	-74	-324	-71.9
Long-Term Debt Issued	3	51.3	65	286.5	80
Long-Term Debt Repaid	-220.3	-48.7	-25.6	-160.8	-156.4
Net Debt Issued (Repaid)	-217.3	2.6	39.4	125.7	-76.4
Issuance of Common Stock	0.3	1.5	-	181	169.8
Repurchase of Common Stock	-66.4	-	-	-	-
Other Financing Activities	-	-	-	-4.3	-4.9
Financing Cash Flow	-433.7	4.1	39.4	302.4	88.5
Net Cash Flow	48	-56	-1	-13	37
Free Cash Flow	23.8	-34.1	17.2	-0.5	15.9
Free Cash Flow Growth	-	-	-	-	3080.00%
Free Cash Flow Margin	7.82%	-11.67%	4.50%	-0.16%	8.28%
Free Cash Flow Per Share	0.27	-0.35	0.18	-0.01	0.29
Cash Interest Paid	-	-	-	2.6	1.2
Cash Income Tax Paid	4.8	2	8.3	6.3	2.5
Levered Free Cash Flow	344.54	-307.71	23.26	28.91	41.7
Unlevered Free Cash Flow	346.03	-304.38	27.01	30.85	42.93
Change in Net Working Capital	-323.6	336	12.1	5.5	-21.9

Source: S&P Global Market Intelligence. Standard template. Financial Sources.